A clinical trial to study the effects of two drugs, lignocaine and esmolol for decreasing optic nerve sheath diameter in patients undergoing laryngoscopy and endotracheal intubation

COMPARISON OF INTRAVENOUS LIGNOCAINE WITH ESMOLOL FOR ATTENUATING INCREASE IN OPTIC NERVE SHEATH DIAMETER DURING LARYNGOSCOPY AND ENDOTRACHEAL INTUBATION - NIL

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/03/064679

Enrollment

100

Registered

2024-03-22

Start date

Unknown

Completion date

Unknown

Last updated

2024-04-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: H470- Disorders of optic nerve, not elsewhere classified Health Condition 2: O- Medical and Surgical

Interventions

Intervention1: Intravenous lignocaine and esmolol: Intravenous lignocaine 1.5 mg/kg and esmolol 0.5 mg/kg, 180 seconds before laryngoscopy and endotracheal intubation Control Intervention1: intravenou

Eligibility

Inclusion criteria

Inclusion criteria: ASA Grade 1 and 2

Exclusion criteria

Exclusion criteria: Patients with psychiatric illness/ any space occupying lesion in CNS, on beta blockers, known eye disease, difficult airway, allergic to lignocaine.

Design outcomes

Primary

Measure	Time frame
Optic nerve sheath diameter using ocular ultrasonographyTimepoint: Optic nerve sheath diameter before, at after 5, 10, 15 minutes of laryngoscopy and endotracheal intubation	—

Secondary

Measure	Time frame
Heart rate and blood pressure valuesTimepoint: Throughout the procedure after every 10 minutes	—

Countries

India

Contacts

Public ContactDr Sonali Banwait

VMMC & Safdarjung Hospital, New Delhi

sonalibanwait@yahoo.co.in9811783404

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026